Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes

Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.barrons.com)